ANVS Projected Dividend Yield
Annovis Bio Inc ( NYSE : ANVS )Annovis Bio is a clinical stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD) and Parkinson's disease (PD). Co.'s pipeline consists of: its primary product candidate, Buntanetap, which is an orally administered drug being developed for chronic indications such as AD and PD; ANVS405, which is an intravenous drug being developed for acute indications, and is focused on protecting the brain after TBI and/or stroke; as well as ANVS301, which is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. 20 YEAR PERFORMANCE RESULTS |
ANVS Dividend History Detail ANVS Dividend News ANVS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |